Dr. Clay Siegall has made it his mission in life to help cancer patients. He founded Seattle Genetics in 1998 and has served as the company’s Chief Executive Officer, President, and Chairman of the Board. Ever since he founded the company they have made great strides in cancer research and advanced therapies for cancer patients.
Dr. Siegall earned his Bachelor’s degree in Zoology from the University of Maryland and his Ph.D. in Genetics from The George Washington University. He started his professional career at the Bristol-Myers Squibb Pharmaceutical Research Institute where he worked as a Senior Research Investigator. He has also worked at the National Cancer Institute as a Principal Scientist, Staff Fellow, and Biotechnology Fellow. With the knowledge he gained from his education and career he decided to found his own cancer research company, Seattle Genetics, in Bothell, Washington.
Under the guidance of Dr. Siegall, Seattle Genetics has been developing a number of cancer drugs, in particular working with antibody-drug conjugates. The company’s first cancer drug to be released was ADCETRIS which was approved by the FDA in 2011. ADCETRIS is now approved for use in more than 60 countries and has helped hundreds of thousands of cancer patients recover.
Under the helm of Dr. Siegall, the company has raised more than $1.2 billion in funding. He has also forged partnerships with other pharmaceutical companies including AbbVie, GlaxoSmithKline, and Pfizer. Dr. Siegall holds 15 patents and has written more than 70 scientific articles. Additionally, he is on the editorial board of three peer-reviewed scientific journals.
Dr. Siegall has won a number of awards during his ground-breaking career. Among these is the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year, as well as 2013 Alumnus of they Year for Computer, Math and Natural History given to him by the University of Maryland.
In addition to his work with Seattle Genetics, Dr. Clay Siegall sits on the Board of Directors for three other pharmaceutical companies. These companies are Alder Biopharmaceuticals Inc., Mirna Therapeutics, Inc., and Ultragenyx Pharmaceutical. He has become one of the most well-respected doctors in the field of cancer research.